复方斑蝥胶囊对乳腺癌术后化疗患者免疫功能的影响
|
摘要
目的:研究复方斑蝥胶囊对乳腺癌术后化疗患者免疫功能的影响。方法:选取2012年5月—2015年5月医院收治的进行乳腺癌术后化疗患者78例作为研究对象,随机分为观察组和对照组,每组39例.对照组患者给予乳腺癌术后常规化疗治疗.观察组患者在给予常规化疗基础上采用复方斑蝥胶囊治疗.比较两组患者临床疗效、症状积分、Ig A与Ig M水平、T细胞亚群、血小板与白细胞计数、生活质量及不良反应情况。结果:观察组总有效率87.18%高于对照组总有效率66.66%,差异有统计学意义(P<0.05)。治疗6周及9周,观察组患者症状积分都低于相同治疗阶段对照组,差异均有统计学意义(P<0.01)。治疗后,观察组患者Ig A及Ig M水平都高于对照组,差异均有统计学意义(P<0.01)。治疗后,观察组患者CD+4/CD+8、CD+8、CD+4及CD+3水平都低于对照组,差异均有统计学意义(P<0.01)。治疗后,观察组患者血小板及白细胞计数水平都高于对照组,差异均有统计学意义(P<0.01)。观察组生活质量改善率87.18%高于对照组生活质量改善率64.10%,差异有统计学意义(P<0.05)。结论:复方斑蝥胶囊应用于乳腺癌术后化疗患者,能够有效缓解化疗后免疫球蛋白Ig A与Ig M水平、T细胞亚群、血小板及白细胞计数降低趋势,改善患者生活质量。
Objective: To study the effect of Compound Cantharis Capsule on immune function in patients with breast cancer after operation and chemotherapy. Methods: 78 cases of breast cancer patients treated with chemotherapy were selected as the research objects and were randomly divided into observation group and control group,39 cases in each group in May 2015 to May 2012. Control group: conventional chemotherapy for breast cancer. Observation group: conventional chemotherapy with Compound Cantharidin Capsules. The clinical efficacy,symptom score,Ig A and Ig M levels,T cell subsets,platelet count,white blood cell count,quality of life and adverse reactions were compared between the two groups.Results: The total effective rate of the observation group was 66. 66%,higher than that of the control group( 87. 18%).The difference was statistically significant( P < 0. 05). After treatment for 6 and 9 weeks,the symptom scores in the observation group were lower than those in the control group and the differences were statistically significant( P < 0. 01).After treatment,the levels of Ig A and Ig M in the observation group were significantly higher than those in the control group and the difference was statistically significant( P < 0. 01). After treatment,the levels of CD + 4 / CD + 8,CD + 4,CD + 8and CD + 3 in the observation group were significantly lower than those in the control group( P < 0. 01). After treatment,blood platelet and leukocyte count in the observation group were significantly higher than those in the control group and the difference was statistically significant( P < 0. 01). The improvement rate of life quality in the observation group was64. 10%,higher than 87. 18% in the control group and the difference was statistically significant( P < 0. 05). Conclusion: Compound Cantharidin Capsules used in postoperative breast cancer patients undergoing chemotherapy can effectively alleviate chemotherapy after immune globulin Ig A and Ig M levels,T cell subsets,platelets and white blood cell count decreasing and can improve the quality of life of the patients.
Objective: To study the effect of Compound Cantharis Capsule on immune function in patients with breast cancer after operation and chemotherapy. Methods: 78 cases of breast cancer patients treated with chemotherapy were selected as the research objects and were randomly divided into observation group and control group,39 cases in each group in May 2015 to May 2012. Control group: conventional chemotherapy for breast cancer. Observation group: conventional chemotherapy with Compound Cantharidin Capsules. The clinical efficacy,symptom score,Ig A and Ig M levels,T cell subsets,platelet count,white blood cell count,quality of life and adverse reactions were compared between the two groups.Results: The total effective rate of the observation group was 66. 66%,higher than that of the control group( 87. 18%).The difference was statistically significant( P < 0. 05). After treatment for 6 and 9 weeks,the symptom scores in the observation group were lower than those in the control group and the differences were statistically significant( P < 0. 01).After treatment,the levels of Ig A and Ig M in the observation group were significantly higher than those in the control group and the difference was statistically significant( P < 0. 01). After treatment,the levels of CD + 4 / CD + 8,CD + 4,CD + 8and CD + 3 in the observation group were significantly lower than those in the control group( P < 0. 01). After treatment,blood platelet and leukocyte count in the observation group were significantly higher than those in the control group and the difference was statistically significant( P < 0. 01). The improvement rate of life quality in the observation group was64. 10%,higher than 87. 18% in the control group and the difference was statistically significant( P < 0. 05). Conclusion: Compound Cantharidin Capsules used in postoperative breast cancer patients undergoing chemotherapy can effectively alleviate chemotherapy after immune globulin Ig A and Ig M levels,T cell subsets,platelets and white blood cell count decreasing and can improve the quality of life of the patients.
引文
[1]山院飞,康鸿斌,张瑞明,等.金龙胶囊对乳腺癌术后化疗患者免疫功能的影响[J].肿瘤防治研究,2014,41(5):456-459.
[2]蒋小君,张春丽,张华.中西医结合减轻乳腺癌术后化疗不良反应的疗效研究[J].内蒙古中医药,2014,33(9):63-64.
[3]张敏依,左亚琴,孙莉.耳穴埋籽对乳腺癌术后患者化疗引起胃肠道反应的影响[J].齐鲁护理杂志,2015,21(4):124.
[4]常彦祥,孙利平,李斌.人参养荣汤对乳腺癌术后化疗不良反应的影响[J].河南中医,2014,34(10):2050-2051.
[5]王志光,林丽珠.疏肝健脾益肾中药联合化疗治疗肝郁型转移性三阴性乳腺癌患者疗效及安全性研究[J].中国全科医学,2015,18(6):620-624.
[6]李天威,赵云清,徐宏,等.扶正健脾抗癌汤减轻乳腺癌患者化疗不良反应临床疗效观察[J].辽宁中医药大学学报,2015,17(2):151-153.
[7]徐海虹,周旭东,冯锦,等.益气健脾疏肝汤对乳腺癌术后化疗患者细胞免疫功能的影响[J].中国中医药科技,2014,21(3):306-307.
[8]武华清,苏秀贞,苏全德,等."隔药灸脐法"对乳腺癌患者免疫功能的影响[J].世界中西医结合杂志,2013,8(6):588-590,593.
[9]毛丹,黄立中,周春花,等.逍遥散加减联合西黄胶囊治疗三阴乳腺癌临床研究[J].中医学报,2014,29(3):316-318.
[10]张春旭.参麦注射液联合CTF方案对乳腺癌术后化疗的疗效观察[J].浙江中医杂志,2013,48(4):287-288.
[11]Arslan C,Dizdar O,Altundag K.Chemotherapy and biological treatment options in breast cancer patients with brain metastasis:an update[J].Expert Opin Pharmacother,2014,15(12):1643-1658.
[12]某些乳腺癌治疗药物也有预防作用[J].中华中医药学刊,2015,33(7):1616.
[13]郭向阳,张亚芬,李炘正.注射用紫杉醇每周方案在乳腺癌术后化疗中的不良反应[J].中国药物与临床,2013,13(12):1638-1639.
[14]MarméF,Werft W,Walter A,el,at.CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline-and taxane-based neoadjuvant chemotherapy for primary breast cancer.[J].Breast cancer research and treatment,2012,132(3):819-831.
[15]庄时刚,毛炜.益血汤联合化疗在乳腺癌术后的应用效果观察[J].中国基层医药,2013,20(22):3466-3467.
[2]蒋小君,张春丽,张华.中西医结合减轻乳腺癌术后化疗不良反应的疗效研究[J].内蒙古中医药,2014,33(9):63-64.
[3]张敏依,左亚琴,孙莉.耳穴埋籽对乳腺癌术后患者化疗引起胃肠道反应的影响[J].齐鲁护理杂志,2015,21(4):124.
[4]常彦祥,孙利平,李斌.人参养荣汤对乳腺癌术后化疗不良反应的影响[J].河南中医,2014,34(10):2050-2051.
[5]王志光,林丽珠.疏肝健脾益肾中药联合化疗治疗肝郁型转移性三阴性乳腺癌患者疗效及安全性研究[J].中国全科医学,2015,18(6):620-624.
[6]李天威,赵云清,徐宏,等.扶正健脾抗癌汤减轻乳腺癌患者化疗不良反应临床疗效观察[J].辽宁中医药大学学报,2015,17(2):151-153.
[7]徐海虹,周旭东,冯锦,等.益气健脾疏肝汤对乳腺癌术后化疗患者细胞免疫功能的影响[J].中国中医药科技,2014,21(3):306-307.
[8]武华清,苏秀贞,苏全德,等."隔药灸脐法"对乳腺癌患者免疫功能的影响[J].世界中西医结合杂志,2013,8(6):588-590,593.
[9]毛丹,黄立中,周春花,等.逍遥散加减联合西黄胶囊治疗三阴乳腺癌临床研究[J].中医学报,2014,29(3):316-318.
[10]张春旭.参麦注射液联合CTF方案对乳腺癌术后化疗的疗效观察[J].浙江中医杂志,2013,48(4):287-288.
[11]Arslan C,Dizdar O,Altundag K.Chemotherapy and biological treatment options in breast cancer patients with brain metastasis:an update[J].Expert Opin Pharmacother,2014,15(12):1643-1658.
[12]某些乳腺癌治疗药物也有预防作用[J].中华中医药学刊,2015,33(7):1616.
[13]郭向阳,张亚芬,李炘正.注射用紫杉醇每周方案在乳腺癌术后化疗中的不良反应[J].中国药物与临床,2013,13(12):1638-1639.
[14]MarméF,Werft W,Walter A,el,at.CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline-and taxane-based neoadjuvant chemotherapy for primary breast cancer.[J].Breast cancer research and treatment,2012,132(3):819-831.
[15]庄时刚,毛炜.益血汤联合化疗在乳腺癌术后的应用效果观察[J].中国基层医药,2013,20(22):3466-3467.